CLIMBAZOLE
本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。
全球证据概览
所解析的身份在 13 个已索引市场数据集中的 8 个有匹配的监管证据:10 条国家记录和 2 条欧盟附件记录。下方列出每项结果和证据缺口。
已解析的物质身份
2-Butanone, 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethyl-
清单限制备注: V/32
9 个匹配或报告的名称
全部 13 个市场的监管证据
打开每条匹配记录,查看其范围、浓度、条件、警示语和官方来源版本。
滑动或横向滚动以查看数据集覆盖范围和后续操作。
| 市场 | 结果 | 记录 | 数据集 | 含义 / 后续操作 |
|---|---|---|---|---|
| European Union EU | 限用 | 2打开记录 1打开记录 2 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | 请查看每条关联记录及其确切条件。 |
| Great Britain GB | Restricted | 2打开记录 1打开记录 2 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | 请查看每条关联记录及其确切条件。 |
| Canada CA | 未找到匹配项 | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Restricted | 2打开记录 1打开记录 2 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | 请查看每条关联记录及其确切条件。 |
| ASEAN ASEAN | Restricted | 2打开记录 1打开记录 2 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | 请查看每条关联记录及其确切条件。 |
| China CN | 未找到匹配项 | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | 未找到匹配项 | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Restricted | 1打开记录 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | 请查看每条关联记录及其确切条件。 |
| United States US | 未找到匹配项 | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | Restricted | 1打开记录 1 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | 请查看每条关联记录及其确切条件。 |
| Brazil BR | 未找到匹配项 | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | Restricted | 1打开记录 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | 请查看每条关联记录及其确切条件。 |
| Saudi Arabia SA | Restricted | 1打开记录 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | 请查看每条关联记录及其确切条件。 |
匹配的市场记录和条件
Great Britain
GB retained Regulation 1223/2009 schedules, effective 15 August 2026New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026South Korea
MFDS Notice 2026-19, effective 18 March 2026Australia
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026附件 II–VI 的精确证据
CLIMBAZOLE
产品范围: Rinse-off anti-dandruff shampoo
最大浓度: 2,0 %
限制: For purposes other than inhibiting the development of micro-organisms in the product. This purpose has to be apparent from the presentation of the product.
CLIMBAZOLE
产品范围: (a) Hair lotions (b) Face creams (c) Foot care products (d) Rinse-off shampoo
最大浓度: (a) 0,2 % (b) 0,2 % (c) 0,2 % (d) 0,5 %
化学身份与性质

Climbazole
1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one is a ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3. It is a hemiaminal ether, a ketone, a member of imidazoles, an aromatic ether and a member of monochlorobenzenes. — ChEBI
- IUPAC 名称
- 1-(4-chlorophenoxy)-1-imidazol-1-yl-3,3-dimethylbutan-2-one
- 分子式
- C15H17ClN2O2
- 分子量
- 292.76 g/mol
- 精确质量
- 292.0978555 Da
- XLogP3
- 3.7
- 拓扑极性表面积
- 44.1 Ų
- 氢键供体
- 0
- 氢键受体
- 3
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:83719
- ChEMBL:CHEMBL1437764
- EPA DTXSID:DTXSID6046555
- PubMed:38795739
- PubMed:21272039
- PubMed:11824557
- PubMed:11552297
- PubMed:11534318
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
官方来源与范围
导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。
打开官方决定